Skip to content

Study · Randomized controlled trial · n = 62 · 2019

5 results

Effect of liraglutide on ambulatory blood pressure in patients with hypertension and type 2 diabetes: A randomized, double-blind, placebo-controlled trial.

Liakos A, Lambadiari V, Bargiota A, Kitsios K, Avramidis I, Kotsa K, Gerou S, Boura P, Tentolouris N, Dimitriadis G, Tsapas A

Diabetes, obesity & metabolism23 Oct 2018Cited by 25 (Europe PMC)

PMID30242948 (opens in a new tab)DOI10.1111/dom.13541 (opens in a new tab)PepBankPUB-30242948
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with hypertension and type 2 diabetes, liraglutide reduced 24-hour systolic blood pressure compared with placebo.

    In plain wordsIn adults with hypertension and type 2 diabetes, liraglutide lowered 24-hour systolic blood pressure more than placebo.

    Peptide
    Liraglutide
    Outcome
    Decrease24-hour ambulatory systolic blood pressure
    Study

    n = 62

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    0.6 mg daily, titrated to 1.2 mg after the first week · 5 weeksAs given in this study (human).

    Measurements

    24-hour SBP difference vs placebo
    −5.73 mm Hg
    liraglutide

    Source sentences

    Summary
    Compared with placebo, liraglutide reduced 24-hour SBP by -5.73 mm Hg (95% confidence interval [CI] -9.81 to -1.65)
    2 context sentences
    Summary · context
    Participants were centrally randomized in a 1:1 ratio to daily liraglutide 0.6 mg, titrated to 1.2 mg after the first week, or placebo for 5 weeks.
    Summary · context
    Of 87 patients assessed for eligibility, 62 (66.1% men) with a mean age of 60.2 years were randomized to liraglutide (n = 31) or placebo (n = 31).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with hypertension and type 2 diabetes, liraglutide had a neutral effect on 24-hour diastolic blood pressure compared with placebo.

    In plain wordsIn adults with hypertension and type 2 diabetes, liraglutide did not change 24-hour diastolic blood pressure compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant change24-hour ambulatory diastolic blood pressure
    Study

    n = 62

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    0.6 mg daily, titrated to 1.2 mg after the first week · 5 weeksAs given in this study (human).

    Source sentences

    Summary
    and had a neutral effect on 24-hour DBP (mean difference - 1.42 mm Hg; 95% CI -4.25 to 1.40)
    2 context sentences
    Summary · context
    Participants were centrally randomized in a 1:1 ratio to daily liraglutide 0.6 mg, titrated to 1.2 mg after the first week, or placebo for 5 weeks.
    Summary · context
    Of 87 patients assessed for eligibility, 62 (66.1% men) with a mean age of 60.2 years were randomized to liraglutide (n = 31) or placebo (n = 31).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with hypertension and type 2 diabetes, liraglutide increased 24-hour heart rate compared with placebo.

    In plain wordsIn adults with hypertension and type 2 diabetes, liraglutide raised heart rate more than placebo.

    Peptide
    Liraglutide
    Outcome
    Increase24-hour heart rate
    Study

    n = 62

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    0.6 mg daily, titrated to 1.2 mg after the first week · 5 weeksAs given in this study (human).

    Measurements

    24-hour heart rate difference vs placebo
    6.16 beats/min
    liraglutide

    Source sentences

    Summary
    whilst increasing 24-hour heart rate by 6.16 beats/min (95% CI 3.25 to 9.07).
    2 context sentences
    Summary · context
    Participants were centrally randomized in a 1:1 ratio to daily liraglutide 0.6 mg, titrated to 1.2 mg after the first week, or placebo for 5 weeks.
    Summary · context
    Of 87 patients assessed for eligibility, 62 (66.1% men) with a mean age of 60.2 years were randomized to liraglutide (n = 31) or placebo (n = 31).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In patients with hypertension and type 2 diabetes, the effects of liraglutide versus placebo on 24-hour blood pressure and heart rate were consistent for daytime and night-time measurements.

    In plain wordsIn adults with hypertension and type 2 diabetes, liraglutide blood pressure and heart rate effects versus placebo were similar by day and night.

    Peptide
    Liraglutide
    Outcome
    MixedDaytime and night-time ambulatory blood pressure and heart rate
    Study

    n = 62

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    0.6 mg daily, titrated to 1.2 mg after the first week · 5 weeksAs given in this study (human).

    Source sentences

    Summary
    Findings were consistent for daytime and night-time measurements.
    2 context sentences
    Summary · context
    Participants were centrally randomized in a 1:1 ratio to daily liraglutide 0.6 mg, titrated to 1.2 mg after the first week, or placebo for 5 weeks.
    Summary · context
    Of 87 patients assessed for eligibility, 62 (66.1% men) with a mean age of 60.2 years were randomized to liraglutide (n = 31) or placebo (n = 31).
  5. 05HumanRandomized controlled trialEfficacy outcome

    In patients with hypertension and type 2 diabetes, liraglutide did not increase urine sodium excretion.

    In plain wordsIn adults with hypertension and type 2 diabetes, liraglutide did not increase sodium loss in urine.

    Peptide
    Liraglutide
    Outcome
    No significant changeUrine sodium excretion
    Study

    n = 62

    Comparator
    Placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    0.6 mg daily, titrated to 1.2 mg after the first week · 5 weeksAs given in this study (human).

    Source sentences

    Summary
    Liraglutide did not increase urine sodium excretion.
    2 context sentences
    Summary · context
    Participants were centrally randomized in a 1:1 ratio to daily liraglutide 0.6 mg, titrated to 1.2 mg after the first week, or placebo for 5 weeks.
    Summary · context
    Of 87 patients assessed for eligibility, 62 (66.1% men) with a mean age of 60.2 years were randomized to liraglutide (n = 31) or placebo (n = 31).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.